None contain semaglutide, tirzepatide, or any prescription GLP-1 receptor agonist
Within this group, 1,086 patients had a history of fracture, representing 8.9% of the total included patient population
Confirm the fragment region, the CJC1295 variant, the Ipamorelin identity, and the quantity assigned to each
1 If confirmed, the finding could eventually allow physicians to optimize GLP-1 dosing strategies with cardiovascular outcomes in mind, distinct from weight management goals
For patients struggling with weight, the difference between a medication that produces 15% weight loss versus one causing weight gain is transformative